ESMO 2024 – Regeneron's fianlimab do-over
Response rates in a key group shrink from 62% to 39% as the company blames a “clerical error”.
ESMO 2024 movers – VEGF bispecifics win, TIGIT loses
After a conference lacking the wow factor, biotech winners and losers emerge.
ESMO 2024 – Astellas defends its degrader
Despite seeing dose-limiting toxicities, the group is going higher with its KRAS G12D project.
ESMO 2024 – Torl challenges BioNTech in Claudin6
Efficacy with Torl’s ADC looks in line, while toxicity with BNT211 still looms large.
ESMO 2024 – Scorpion joins Relay in the alpha club
What Relay managed with a combo Scorpion might be able to do with STX-478 monotherapy.
ESMO 2024 – a role for immunotherapy in ovarian cancer
If the therapeutic window remains open, OncoC4/BioNTech’s gotistobart could hold promise.
